3/4
05:42 pm
scyx
Scynexis: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Scynexis: Q4 Earnings Snapshot [Yahoo! Finance]
3/4
04:58 pm
scyx
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/4
04:20 pm
scyx
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
Low
Report
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
2/26
08:34 am
scyx
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 [Yahoo! Finance]
Medium
Report
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 [Yahoo! Finance]
2/26
08:23 am
scyx
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
High
Report
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
1/28
08:00 am
scyx
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Medium
Report
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
1/21
10:32 am
scyx
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
Medium
Report
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 [Yahoo! Finance]
1/21
08:00 am
scyx
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
High
Report
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
12/22
09:07 am
scyx
SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]
Medium
Report
SCYNEXIS granted Nasdaq extension to regain bid price compliance [Seeking Alpha]
12/22
08:55 am
scyx
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]
Low
Report
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement [Yahoo! Finance]
12/22
08:00 am
scyx
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Low
Report
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement